Lantheus Holdings Inc. (LNTH) Upgraded by Zacks Investment Research to Buy
Zacks Investment Research upgraded shares of Lantheus Holdings Inc. (NASDAQ:LNTH) from a hold rating to a buy rating in a report published on Wednesday morning. The firm currently has $9.00 price objective on the stock.
According to Zacks, “Lantheus Holdings, Inc. is involved in developing, manufacturing, selling and distributing diagnostic medical imaging agents and products for diagnosis of cardiovascular and other diseases. It serves to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, radiopharmacies and wholesalers. Lantheus Holdings, Inc. is based in NORTH BILLERICA, United States. “
A number of other equities research analysts also recently commented on LNTH. Credit Suisse Group AG assumed coverage on shares of Lantheus Holdings in a research report on Friday, September 23rd. They issued a neutral rating and a $8.00 price objective for the company. Jefferies Group restated a buy rating on shares of Lantheus Holdings in a research report on Friday, August 5th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Lantheus Holdings has an average rating of Buy and a consensus target price of $7.80.
Shares of Lantheus Holdings (NASDAQ:LNTH) opened at 7.77 on Wednesday. The stock has a 50 day moving average price of $8.46 and a 200-day moving average price of $4.60. The stock has a market capitalization of $236.11 million, a price-to-earnings ratio of 8.77 and a beta of 0.45. Lantheus Holdings has a 52-week low of $1.76 and a 52-week high of $10.10.
Lantheus Holdings (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, August 4th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.18. Lantheus Holdings had a negative return on equity of 11.75% and a net margin of 9.00%. The firm had revenue of $78 million for the quarter, compared to analyst estimates of $72.66 million. On average, equities research analysts predict that Lantheus Holdings will post $0.55 EPS for the current fiscal year.
Several hedge funds have recently made changes to their positions in the stock. Brigade Capital Management LP bought a new stake in shares of Lantheus Holdings during the second quarter valued at about $5,219,000. Globeflex Capital L P bought a new stake in shares of Lantheus Holdings during the second quarter valued at about $1,410,000. BlackRock Institutional Trust Company N.A. boosted its stake in shares of Lantheus Holdings by 4.1% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 202,183 shares of the company’s stock valued at $742,000 after buying an additional 7,875 shares in the last quarter. Gabelli Funds LLC boosted its stake in shares of Lantheus Holdings by 22.2% in the second quarter. Gabelli Funds LLC now owns 165,000 shares of the company’s stock worth $606,000 after buying an additional 30,000 shares during the period. Finally, GSA Capital Partners LLP boosted its stake in shares of Lantheus Holdings by 3.7% in the second quarter. GSA Capital Partners LLP now owns 154,322 shares of the company’s stock worth $566,000 after buying an additional 5,500 shares during the period. 30.15% of the stock is owned by institutional investors.
Lantheus Holdings Company Profile
Lantheus Holdings, Inc develops, manufactures and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. The Company’s portfolio of approximately 10 commercial products is spread across a range of imaging modalities.
Receive News & Stock Ratings for Lantheus Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc. and related stocks with our FREE daily email newsletter.